MX2024004416A - Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. - Google Patents
Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.Info
- Publication number
- MX2024004416A MX2024004416A MX2024004416A MX2024004416A MX2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A
- Authority
- MX
- Mexico
- Prior art keywords
- ehmt1
- ehmt2
- therapeutic use
- novel modulators
- novel
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 abstract 1
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 abstract 1
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 abstract 1
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256057P | 2021-10-15 | 2021-10-15 | |
| US202263390438P | 2022-07-19 | 2022-07-19 | |
| PCT/US2022/046761 WO2023064586A1 (en) | 2021-10-15 | 2022-10-14 | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004416A true MX2024004416A (es) | 2024-07-09 |
Family
ID=84357982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004416A MX2024004416A (es) | 2021-10-15 | 2022-10-14 | Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368139A1 (https=) |
| EP (1) | EP4416143A1 (https=) |
| JP (1) | JP2024538128A (https=) |
| KR (1) | KR20240148310A (https=) |
| AU (1) | AU2022366869A1 (https=) |
| CA (1) | CA3234693A1 (https=) |
| IL (1) | IL311999A (https=) |
| MX (1) | MX2024004416A (https=) |
| WO (1) | WO2023064586A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602242B (zh) * | 2023-05-08 | 2024-01-23 | 中国水产科学研究院珠江水产研究所 | 一种提高反季鱼苗成活率的方法 |
| WO2025155882A1 (en) * | 2024-01-19 | 2025-07-24 | Icahn School Of Medicine At Mount Sinai | G9a/glp degradation / disruption compounds and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| PL3442947T3 (pl) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| US20200039998A1 (en) * | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| JP2021500326A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法 |
| AU2018353139A1 (en) * | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
-
2022
- 2022-10-14 JP JP2024522501A patent/JP2024538128A/ja active Pending
- 2022-10-14 KR KR1020247016027A patent/KR20240148310A/ko active Pending
- 2022-10-14 MX MX2024004416A patent/MX2024004416A/es unknown
- 2022-10-14 US US18/701,092 patent/US20240368139A1/en active Pending
- 2022-10-14 AU AU2022366869A patent/AU2022366869A1/en active Pending
- 2022-10-14 IL IL311999A patent/IL311999A/en unknown
- 2022-10-14 CA CA3234693A patent/CA3234693A1/en active Pending
- 2022-10-14 WO PCT/US2022/046761 patent/WO2023064586A1/en not_active Ceased
- 2022-10-14 EP EP22802794.2A patent/EP4416143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022366869A1 (en) | 2024-05-02 |
| KR20240148310A (ko) | 2024-10-11 |
| US20240368139A1 (en) | 2024-11-07 |
| EP4416143A1 (en) | 2024-08-21 |
| IL311999A (en) | 2024-06-01 |
| JP2024538128A (ja) | 2024-10-18 |
| WO2023064586A1 (en) | 2023-04-20 |
| CA3234693A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020163823A3 (en) | Therapeutic agents and methods of treatment | |
| PH12021551409A1 (en) | Kif18a inhibitors | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| MX2025013504A (es) | Inhibidores de kras de anillo fundido para el tratamiento de enfermedades | |
| MX2024006824A (es) | Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos. | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| CR20230057A (es) | Compuestos tríciclicos de urea como inhibidores de jak2 v617f | |
| MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
| CR20230408A (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| MX2024011254A (es) | Moduladores de nlrp3 | |
| WO2019166412A9 (en) | Modulation of pla2-g1b in therapy | |
| MX2024004416A (es) | Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| PH12022552447A1 (en) | Nlrp3 modulators | |
| WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| EP4582446A3 (en) | Methods of treating al amyloidosis | |
| MX2024011378A (es) | Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2). | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| WO2020231739A3 (en) | Compounds and methods for treating cancer | |
| MX2025005544A (es) | Moduladores de gpr17 y sus usos |